reported a narrower-than-expected first-quarter loss as revenue for the company that's mapping the human genome more than doubled.
The genomics technology company posted a loss of $25.7 million, or 43 cents a share, compared with a loss of $19.4 million, or 38 cents a share, in the year-ago period. Analysts expected the company to lose 57 cents a share, according to an
Revenue for the quarter rose to $18.3 million from $8.3 million last year, fueled by an increase in subscription agreements. Celera is a unit of
Shares of Celera recently gained $3.38, or 5.1%, to $69 in
New York Stock Exchange